Phibro Animal Health Corporation (PAHC)
Receivables turnover
| Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 1,296,220 | 1,017,680 | 977,889 | 942,300 | 833,350 |
| Receivables | US$ in thousands | 227,983 | 169,452 | 163,479 | 166,537 | 146,852 |
| Receivables turnover | 5.69 | 6.01 | 5.98 | 5.66 | 5.67 |
June 30, 2025 calculation
Receivables turnover = Revenue ÷ Receivables
= $1,296,220K ÷ $227,983K
= 5.69
The receivables turnover ratio of Phibro Animal Health Corporation demonstrates relatively stable performance over the period from June 30, 2021, to June 30, 2025. Specifically, the ratio was 5.67 in 2021, slightly decreasing to 5.66 in 2022, indicating consistency in the company's ability to collect its receivables during that year.
In 2023, the ratio increased to 5.98, suggesting an improvement in receivables collection efficiency, with the company able to convert its accounts receivable into cash more quickly than in previous years. This upward trend continued into 2024, with the ratio reaching 6.01, highlighting further enhancement in collection processes or improved credit management.
However, in 2025, the receivables turnover ratio declined to 5.69, again approaching the earlier levels observed in 2021 and 2022. This minor decrease may reflect a slight slowdown in collection efficiency or changes in credit policies, but the ratio remains within a comparable range over the analyzed period.
Overall, the ratios indicate that Phibro Animal Health Corporation has maintained a relatively consistent receivables management performance, with a brief period of improvement in 2023 and 2024. The slight variation in the ratio across these years suggests stable credit and collection practices without significant fluctuation in receivables turnover efficiency.
Peer comparison
Jun 30, 2025